Protalix BioTherapeutics, Inc.

PLX · AMEX
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$2,355$164-$3,619$6,494
Dep. & Amort.$372$360$346$334
Deferred Tax$59$231-$113$0
Stock-Based Comp.$598$427$540$654
Change in WC-$7,136-$6,899-$1,840-$3,447
Other Non-Cash$20$484-$372-$44
Operating Cash Flow-$3,732-$5,233-$5,058$3,991
Investing Activities
PP&E Inv.-$498-$431-$306-$425
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$6-$7-$6-$14,895
Investing Cash Flow-$504-$438-$312-$15,320
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$3,951$2,861$3,626
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$153$2,215$0
Financing Cash Flow$0$4,104$5,076$3,626
Forex Effect-$12$4-$8$54
Net Chg. in Cash-$4,248-$1,563-$302-$7,649
Supplemental Information
Beg. Cash$17,895$19,458$19,760$27,409
End Cash$13,647$17,895$19,458$19,760
Free Cash Flow-$4,230-$5,664-$5,364$3,566
Protalix BioTherapeutics, Inc. (PLX) Financial Statements & Key Stats | AlphaPilot